Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Glioblastoma Treatment Modalities besides Surgery.

Zhang H, Wang R, Yu Y, Liu J, Luo T, Fan F.

J Cancer. 2019 Aug 27;10(20):4793-4806. doi: 10.7150/jca.32475. eCollection 2019. Review.

2.

Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review.

Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, Sebastian N, Giglio P, Puduvalli V, Gonzalez J, Palmer JD.

Cancers (Basel). 2019 Feb 2;11(2). pii: E174. doi: 10.3390/cancers11020174. Review.

3.

Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.

Zhu P, Zhu JJ.

Chin Clin Oncol. 2017 Aug;6(4):41. doi: 10.21037/cco.2017.06.29. Review.

4.

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

Polivka J Jr, Polivka J, Holubec L, Kubikova T, Priban V, Hes O, Pivovarcikova K, Treskova I.

Anticancer Res. 2017 Jan;37(1):21-33. Review.

PMID:
28011470
5.

Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.

Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.

J Neurosurg. 2014 Sep;121(3):543-53. doi: 10.3171/2014.5.JNS132392. Epub 2014 Jul 4.

PMID:
24995786
6.

Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.

Carter TC, Medina-Flores R, Lawler BE.

Biomed Res Int. 2018 Dec 31;2018:6204676. doi: 10.1155/2018/6204676. eCollection 2018.

7.

Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.

Chin C, Lunking ES, de la Fuente M, Ayad NG.

Front Oncol. 2018 Nov 13;8:521. doi: 10.3389/fonc.2018.00521. eCollection 2018. Review.

8.

Current trends in targeted therapies for glioblastoma multiforme.

Ohka F, Natsume A, Wakabayashi T.

Neurol Res Int. 2012;2012:878425. doi: 10.1155/2012/878425. Epub 2012 Mar 5.

9.

Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction.

Mallick S, Gandhi AK, Rath GK.

Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):229-37. doi: 10.4103/0971-5851.171543. Review.

10.

Glioblastoma multiforme: State of the art and future therapeutics.

Wilson TA, Karajannis MA, Harter DH.

Surg Neurol Int. 2014 May 8;5:64. doi: 10.4103/2152-7806.132138. eCollection 2014. Review.

11.

Natural products: a hope for glioblastoma patients.

Vengoji R, Macha MA, Batra SK, Shonka NA.

Oncotarget. 2018 Apr 24;9(31):22194-22219. doi: 10.18632/oncotarget.25175. eCollection 2018 Apr 24. Review.

12.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

13.

Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.

Birol Sarica F, Tufan K, Cekinmez M, Sen O, Cem Onal H, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Nur Altinors M.

J Neurosurg Sci. 2010 Mar;54(1):7-19.

PMID:
20436394
14.

Towards tailored therapy of glioblastoma multiforme.

Rekers NH, Sminia P, Peters GJ.

J Chemother. 2011 Aug;23(4):187-99. Review.

PMID:
21803695
15.

Management of glioblastoma.

Aoki T, Hashimoto N, Matsutani M.

Expert Opin Pharmacother. 2007 Dec;8(18):3133-46. Review.

PMID:
18035958
16.

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Neagu MR, Reardon DA.

Curr Treat Options Oncol. 2015 Nov;16(11):54. doi: 10.1007/s11864-015-0371-3. Review.

PMID:
26454859
17.

Gene therapy for malignant glioma.

Okura H, Smith CA, Rutka JT.

Mol Cell Ther. 2014 Jul 8;2:21. doi: 10.1186/2052-8426-2-21. eCollection 2014. Review.

18.

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.

Ung N, Yang I.

J Neurooncol. 2015 Jul;123(3):473-81. doi: 10.1007/s11060-015-1814-1. Epub 2015 Jun 13. Review.

PMID:
26070553
19.

Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.

Conti S, Vexler A, Edry-Botzer L, Kalich-Philosoph L, Corn BW, Shtraus N, Meir Y, Hagoel L, Shtabsky A, Marmor S, Earon G, Lev-Ari S.

PLoS One. 2018 Jul 3;13(7):e0198627. doi: 10.1371/journal.pone.0198627. eCollection 2018.

20.

Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.

Wang H, Cai S, Bailey BJ, Reza Saadatzadeh M, Ding J, Tonsing-Carter E, Georgiadis TM, Zachary Gunter T, Long EC, Minto RE, Gordon KR, Sen SE, Cai W, Eitel JA, Waning DL, Bringman LR, Wells CD, Murray ME, Sarkaria JN, Gelbert LM, Jones DR, Cohen-Gadol AA, Mayo LD, Shannon HE, Pollok KE.

J Neurosurg. 2017 Feb;126(2):446-459. doi: 10.3171/2016.1.JNS152513. Epub 2016 May 13.

Supplemental Content

Support Center